Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: A single-center experience

Takayuki Katsuno, Takenori Ozaki, Hangsoo Kim, Noritoshi Kato, Yasuhiro Suzuki, Shinichi Akiyama, Takuji Ishimoto, Tomoki Kosugi, Naotake Tsuboi, Yasuhiko Ito, Shoichi Maruyama

研究成果: Article査読

4 被引用数 (Scopus)

抄録

To date, a recognized treatment for refractory membranous nephropathy (MN) has not been established. Recently, several reports have indicated the efficacy of rituximab as a novel treatment option. However, only a few published accounts exist of rituximab therapy for idiopathic MN (IMN) in the Asian population. We present the cases of three IMN patients who were treated with single-dose rituximab after they showed no response to conventional therapies, including corticosteroids, cyclosporine, cyclophosphamide, mizoribine, and mycophenolate mofetil. Although one case showed no response, a complete or incomplete remission was achieved in the other two cases. Rituximab may therefore be a beneficial treatment option for IMN.

本文言語English
ページ(範囲)1679-1686
ページ数8
ジャーナルInternal Medicine
56
13
DOI
出版ステータスPublished - 2017
外部発表はい

All Science Journal Classification (ASJC) codes

  • 内科学

フィンガープリント

「Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: A single-center experience」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル